NASDAQ:ABMDABIOMED Stock Price, Forecast & News

ABIOMED's stock was trading at $151.13 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ABMD shares have increased by 103.4% and is now trading at $307.35.
View which stocks have been most impacted by COVID-19.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for ABIOMED.

ABIOMED is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for ABIOMED.

ABIOMED, Inc. (NASDAQ:ABMD) posted its quarterly earnings data on Thursday, August, 6th. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.20 by $0.38. The medical equipment provider earned $164.90 million during the quarter, compared to the consensus estimate of $144.12 million. ABIOMED had a return on equity of 16.17% and a net margin of 19.88%. ABIOMED's revenue was down 20.6% on a year-over-year basis. During the same quarter last year, the company earned $1.00 EPS.
View ABIOMED's earnings history.

8 brokers have issued 12-month price targets for ABIOMED's shares. Their forecasts range from $155.00 to $335.00. On average, they anticipate ABIOMED's share price to reach $236.75 in the next year. This suggests that the stock has a possible downside of 23.0%.
View analysts' price targets for ABIOMED.

Media coverage about ABMD stock has been trending somewhat negative on Friday, InfoTrie reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ABIOMED earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave news stories about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about ABIOMED.

Some companies that are related to ABIOMED include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Stryker (SYK), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Steris (STE).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Netflix (NFLX), Intuitive Surgical (ISRG), salesforce.com (CRM), Square (SQ) and Adobe (ADBE).

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

ABIOMED's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.68%), Bank of New York Mellon Corp (1.38%), Jackson Square Partners LLC (1.36%), William Blair Investment Management LLC (1.28%), Blair William & Co. IL (0.81%) and New York State Common Retirement Fund (0.60%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Martin P Sutter, Michael G Howley and Paul Thomas.
View institutional ownership trends for ABIOMED.

ABMD stock was sold by a variety of institutional investors in the last quarter, including Baird Financial Group Inc., Vanguard Group Inc., Barclays PLC, Federated Hermes Inc., Rhenman & Partners Asset Management AB, Bank of America Corp DE, Assenagon Asset Management S.A., and Goldman Sachs Group Inc.. Company insiders that have sold ABIOMED company stock in the last year include Dorothy E Puhy, and Paul Thomas.
View insider buying and selling activity for ABIOMED.

ABMD stock was acquired by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, William Blair Investment Management LLC, Blair William & Co. IL, Scout Investments Inc., Villere ST Denis J & Co. LLC, Sumitomo Mitsui Trust Holdings Inc., Marathon Asset Management LLP, and Bank of New York Mellon Corp.
View insider buying and selling activity for ABIOMED.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABMD stock can currently be purchased for approximately $307.35.

ABIOMED has a market capitalization of $13.85 billion and generates $840.88 million in revenue each year. The medical equipment provider earns $203.01 million in net income (profit) each year or $4.74 on an earnings per share basis. ABIOMED employs 1,536 workers across the globe.

The official website for ABIOMED is www.abiomed.com.

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]